Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a private placement
Mandate

Vinge advises Cinclus Pharma in connection with a private placement

May 20, 2022 Intellectual Property Capital Markets and Public M&A Corporate Tax

Vinge has advised the biopharmaceutical development company Cinclus Pharma in connection with a private placement of approximately SEK 240 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of linaprazan glurate, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD), accelerate the Company’s commercialization strategy and broaden the shareholder base.

Vinge’s team consisted primarily of Dain Hård Nevonen, Amanda Knutsson, Stojan Arnerstål, Maria Schultzberg and Anna Svensson.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025